Related Experiment Video
Updated: Dec 24, 2025
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Mechanistic Insights for Optimizing PSMA Radioligand Therapy
Aravind S Ravi Kumar1,2, Michael S Hofman1,2
1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. aravind.ravikumar@petermac.org michael.hofman@petermac.org.
Abstract:
PSMA radioligand therapy is a promising new class of therapy for prostate cancer. Heterogeneity of PSMA expression is an important factor explaining variability in clinical results. The ability to visualize the target with theranostics provides unique mechanistic insights. Potential clinically applicable strategies to improve patient selection and optimize therapeutic efficacy are discussed.See related article by Current et al., p. 2946.
Insights
Prostate cancer treatment using PSMA radioligand therapy shows promise. Visualizing the target with theranostics helps understand treatment variability and improve patient selection for better results.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Prostate cancer remains a significant health concern.
- PSMA radioligand therapy is an emerging treatment modality.
- Variability in clinical outcomes is linked to PSMA expression heterogeneity.
Purpose of the Study:
- To explore the role of PSMA expression heterogeneity in prostate cancer treatment.
- To discuss the application of theranostics for visualizing PSMA targets.
- To identify strategies for optimizing patient selection and therapeutic efficacy.
Main Methods:
- Review of current literature on PSMA radioligand therapy.
- Analysis of theranostic approaches for PSMA visualization.
- Discussion of clinical strategies for patient stratification.
Main Results:
- PSMA expression heterogeneity significantly impacts treatment response.
- Theranostics offer mechanistic insights into treatment efficacy.
- Improved patient selection can enhance therapeutic outcomes.
Conclusions:
- PSMA radioligand therapy holds significant potential for prostate cancer.
- Theranostic visualization is key to understanding and overcoming treatment variability.
- Clinical strategies are needed to optimize patient selection and maximize treatment benefits.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
09:08Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
Published on: December 20, 2024
